Lingating, Esterlita .
HRN: 06-81-30 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/04/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
05/04/2024
05/18/2024
IV
4.5
Q8
Infected Wound, Breast
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes